SEARCH

SEARCH BY CITATION

References

  • 1
    Hayden FG. Newer influenza antivirals, biotherapeutics and combinations. Influenza Other Respi Viruses 2013; 7(Suppl 1):6375.
  • 2
    Wathen MW, Barro M, Bright RA. Antivirals in seasonal and pandemic influenza–future perspectives. Influenza Other Respi Viruses 2013; 7(Suppl 1):7680.
  • 3
    Yang SG, Cao B, Liang LR et al. Antiviral therapy and outcomes of patients with pneumonia caused by influenza A pandemic (H1N1) virus. PLoS ONE 2012; 7:e29652.
  • 4
    Hsu J, Santesso N, Mustafa R et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med 2012; 156:512524.
  • 5
    Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis 2013; 207:553563.
  • 6
    Louie JK, Yang S, Acosta M et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A(H1N1)pdm09. Clin Infect Dis 2012; 55:11981204.
  • 7
    Yu H, Liao Q, Yuan Y et al. Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China. BMJ 2010; 341:c4779.
  • 8
    Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367:18141820.
  • 9
    Khan G. A novel coronavirus capable of lethal human infections: an emerging picture. Virol J 2013; 10:66.
  • 10
    The Health Protection Agency (HPA) UK Novel Coronavirus Investigation team. Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013. Euro Surveill 2013; 18:pii=20427.
  • 11
    Bermingham A, Chand MA, Brown CS et al. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveill 2012; 17:20290.
  • 12
    Hui DS, Chan PK. Severe acute respiratory syndrome and coronavirus. Infect Dis Clin North Am 2010; 24:619638.
  • 13
    de Wilde AH, Zevenhoven-Dobbe JC, van der Meer Y et al. Cyclosporin A inhibits the replication of diverse coronaviruses. J Gen Virol 2011; 92(Pt 11):25422548.
  • 14
    Barnard DL, Day CW, Bailey K et al. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antivir Chem Chemother 2006; 17:275284.
  • 15
    Haagmans BL, Osterhaus AD. Coronaviruses and their therapy. Antiviral Res 2006; 71:397403.
  • 16
    De Clercq E. Potential antivirals and antiviral strategies against SARS coronavirus infections. Expert Rev Anti Infect Ther 2006; 4:291302.
  • 17
    Gomersall CD. Pro/con clinical debate: steroids are a key component in the treatment of SARS. Crit Care 2004; 8:105107.
  • 18
    Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med 2006; 3:e343.
  • 19
    Wong SS, Yuen KY. The management of coronavirus infections with particular reference to SARS. J Antimicrob Chemother 2008; 62:437441.
  • 20
    Chan KS, Lai ST, Chu CM et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J 2003; 9:399406.
  • 21
    Chu CM, Cheng VC, Hung IF et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004; 59:252256.
  • 22
    Barnard DL, Day CW, Bailey K et al. Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin. Antiviral Res 2006; 71:5363.
  • 23
    Ng EK, Ng PC, Hon KL et al. Serial analysis of the plasma concentration of SARS coronavirus RNA in pediatric patients with severe acute respiratory syndrome. Clin Chem 2003; 49:20852088.
  • 24
    Knowles SR, Phillips EJ, Dresser L, Matukas L. Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada. Clin Infect Dis 2003; 37:11391142.
  • 25
    Falzarano D, de Wit E, Martellaro C, Callison J, Munster VJ, Feldmann H. Inhibition of novel beta coronavirus replication by a combination of interferon-alpha2b and ribavirin. Sci Rep 2013; 3:1686.
  • 26
    Haagmans BL, Kuiken T, Martina BE et al. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med 2004; 10:290293.
  • 27
    Zhao J, Wohlford-Lenane C, Zhao J et al. Intranasal treatment with poly(I*C) protects aged mice from lethal respiratory virus infections. J Virol 2012; 86:1141611424.
  • 28
    Smits SL, de Lang A, van den Brand JM et al. Exacerbated innate host response to SARS-CoV in aged non-human primates. PLoS Pathog 2010; 6:e1000756.
  • 29
    Loutfy MR, Blatt LM, Siminovitch KA et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 2003; 290:32223228.
  • 30
    Kindler E, Jonsdottir HR, Muth D et al. Efficient replication of the novel human betacoronavirus EMC on primary human epithelium highlights its zoonotic potential. MBio 2013; 4:e00611e00612.
  • 31
    Chan RW, Chan MC, Agnihothram S et al. Tropism and innate immune responses of the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures. J Virol 2013; 87:66046614.
  • 32
    Belardo G, La Frazia S, Cenciareli O, Carta S, Rossignol JF, Santoro MG. Nitazoxanide, a novel potential anti-influenza drug, acting in synergism with neuraminidase inhibitors [Internet]. Paper presented at: 49th Infectious Disease Society of America Annual Meeting; 2011 Oct 20–23; Boston, MA. Available at http://idsa.confex.com/idsa/2011/webprogram/Paper31075.html. IDSA Annual Meeting Boston: New Approaches to Anti-Viral Therapy Saturday, October 22, 2011. 2012 (Accessed 29 April 2013).
  • 33
    Rossignol JF, Samudrals S, Hoppers M et al. A randomized, double-blind, placebo (PCB) controlled clinical trial of nitazoxanide (NTZ) in adults and adolescents with acute uncomplicated influenza [Internet]. Paper presented at: 49th Infectious Disease Society of America Annual Meeting; 2011 Oct 20-23; Boston, MA. Available at http://idsa.confex.com/idsa/2011/webprogram/Paper33028.html. IDSA Annual Meeting, Boston. LB-35. 10-22-2011 (Accessed 29 April 2013).
  • 34
    ter Meulen J, Bakker AB, van den Brink EN et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 2004; 363:21392141.
  • 35
    Roberts A, Thomas WD, Guarner J et al. Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters. J Infect Dis 2006; 193:685692.
  • 36
    Cheng Y, Wong R, Soo YO et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24:4446.
  • 37
    Yeh KM, Chiueh TS, Siu LK et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother 2005; 56:919922.
  • 38
    Li BJ, Tang Q, Cheng D et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med 2005; 11:944951.
  • 39
    Raj VS, Mou H, Smits SL et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013; 495:251254.
  • 40
    Muller MA, Raj VS, Muth D et al. Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines. MBio 2012; 3:e0051512.
  • 41
    Ip WK, Chan KH, Law HK et al. Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection. J Infect Dis 2005 May 15; 191:16971704.
  • 42
    Zhou Y, Lu K, Pfefferle S et al. A single asparagine-linked glycosylation site of the severe acute respiratory syndrome coronavirus spike glycoprotein facilitates inhibition by mannose-binding lectin through multiple mechanisms. J Virol 2010; 84:87538764.
  • 43
    Michelow IC, Lear C, Scully C et al. High-dose mannose-binding lectin therapy for Ebola virus infection. J Infect Dis 2011; 203:175179.
  • 44
    Nair H, Nokes DJ, Gessner BD et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375:15451555.
  • 45
    Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179186.
  • 46
    Geevarghese B, Simoes EA. Antibodies for prevention and treatment of respiratory syncytial virus infections in children. Antivir Ther 2012;17(1 Pt B):201211.
  • 47
    American Academy of Pediatrics. Respiratory syncytial virus; in Pickering LK (ed): Red Book: 2012 Report of the Committee on Infectious Diseases, 29th. Elk Grove Village, IL: American Academy of Pediatrics, 2012; 609. 2013.
  • 48
    Renaud C, Englund JA. Antiviral therapy of respiratory viruses in haematopoietic stem cell transplant recipients. Antivir Ther 2012; 17(1 Pt B):175191.
  • 49
    Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 2011; 117:27552763.
  • 49a
    Seo S, Campbell AP, Xie H, Chien JW, Leisenring WM, Englund JA, Boeckh M. Outcome of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Hematopoietic Cell Transplant Recipients Receiving Aerosolized Ribavirin: Significance of Stem Cell Source and Oxygen Requirement. Biol Blood Marrow Transplant 2013; 19:589596.
  • 50
    Chemaly RF, Torres HA, Munsell MF et al. An adaptive randomized trial of an intermittent dosing schedule of aerosolized ribavirin in patients with cancer and respiratory syncytial virus infection. J Infect Dis 2012; 206:13671371.
  • 51
    Khanna N, Widmer AF, Decker M et al. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis 2008; 46:402412.
  • 52
    Park SY, Baek S, Lee SO et al. Efficacy of oral ribavirin in hematologic disease patients with paramyxovirus infection: analytic strategy using propensity scores. Antimicrob Agents Chemother 2013; 57:983989.
  • 53
    Ison MG. Antiviral therapies for respiratory viral infections in lung transplant patients. Antivir Ther 2012; 17(1 Pt B):193200.
  • 54
    Fuehner T, Dierich M, Duesberg C et al. Single-centre experience with oral ribavirin in lung transplant recipients with paramyxovirus infections. Antivir Ther 2011; 16:733740.
  • 55
    Lagos R, Devincenzo JP, Munoz A et al. Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children. Pediatr Infect Dis J 2009; 28:835837.
  • 56
    Carbonell-Estrany X, Simoes EA, Dagan R et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 2010; 125:e35e51.
  • 57
    Costello HM, Ray WC, Chaiwatpongsakorn S, Peeples ME. Targeting RSV with vaccines and small molecule drugs. Infect Disord Drug Targets 2012; 12:110128.
  • 58
    Alvarez R, Elbashir S, Borland T et al. RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob Agents Chemother 2009; 53:39523962.
  • 59
    Devincenzo JP. The promise, pitfalls and progress of RNA-interference-based antiviral therapy for respiratory viruses. Antivir Ther 2012; 17(1 Pt B):213225.
  • 60
    Devincenzo J, Lambkin-Williams R, Wilkinson T et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci USA 2010; 107:88008805.
  • 61
    Zamora MR, Budev M, Rolfe M et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med 2011; 183:531538.
  • 62
    Alnylam presents complete results from phase IIb trial with ALN-RSV01, an inhaled RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection. Available at http://www.businesswire.com/news/home/20120904005531/en/Alnylam-Presents-Complete-Results-Phase-IIb-Trial.
  • 63
    Malakhov MP, Aschenbrenner LM, Smee DF et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 2006; 50:14701479.
  • 64
    Belser JA, Lu X, Szretter KJ et al. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis 2007; 196:14931499.
  • 65
    Triana-Baltzer GB, Gubareva LV, Nicholls JM et al. Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS ONE 2009; 4:e7788.
  • 66
    Moss RB, Hansen C, Sanders RL, Hawley S, Li T, Steigbigel RT. A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect Dis 2012; 206:18441851.
  • 67
    Moscona A, Porotto M, Palmer S et al. A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo. J Infect Dis 2010; 202:234241.
  • 68
    Guzman-Suarez BB, Buckley MW, Gilmore ET et al. Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients. Transpl Infect Dis 2012; 14:427433.
  • 69
    Chen YB, Driscoll JP, McAfee SL et al. Treatment of parainfluenza 3 infection with DAS181 in a patient after allogeneic stem cell transplantation. Clin Infect Dis 2011; 53:e77e80.
  • 70
    Drozd DR, Limaye AP, Moss RB et al. DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient. Transpl Infect Dis 2013; 15:E28E32.
  • 71
    Carr MJ, Kajon AE, Lu X et al. Deaths associated with human adenovirus-14p1 infections, Europe, 2009-2010. Emerg Infect Dis 2011; 17:14021408.
  • 72
    Lewis PF, Schmidt MA, Lu X et al. A community-based outbreak of severe respiratory illness caused by human adenovirus serotype 14. J Infect Dis 2009; 199:14271434.
  • 73
    Waye MYM, Sing WS. Anti-viral drugs for human adenoviruses. Pharmaceuticals 2010; 3:33433354.
  • 74
    Morfin F, Dupuis-Girod S, Frobert E et al. Differential susceptibility of adenovirus clinical isolates to cidofovir and ribavirin is not related to species alone. Antivir Ther 2009; 14:5561.
  • 75
    Bhadri VA, Lee-Horn L, Shaw PJ. Safety and tolerability of cidofovir in high-risk pediatric patients. Transpl Infect Dis 2009; 11:373379.
  • 76
    Lindemans CA, Leen AM, Boelens JJ. How I treat adenovirus in hematopoietic stem cell transplant recipients. Blood 2010; 116:54765485.
  • 77
    Hartline CB, Gustin KM, Wan WB et al. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J Infect Dis 2005; 191:396399.
  • 78
    Toth K, Spencer JF, Dhar D et al. Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proc Natl Acad Sci USA 2008; 105:72937297.
  • 79
    Florescu DF, Pergam SA, Neely MN et al. Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Biol Blood Marrow Transplant 2012; 18:731738.
  • 80
    Painter W, Robertson A, Trost LC, Godkin S, Lampert B, Painter G. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob Agents Chemother 2012; 56:27262734.
  • 81
    Hayden FG, Herrington DT, Coats TL et al. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis 2003; 36:15231532.
  • 82
    Pevear DC, Hayden FG, Demenczuk TM, Barone LR, McKinlay MA, Collett MS. Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses. Antimicrob Agents Chemother 2005; 49:44924499.
  • 83
    Lambert JN. Rhinovirus both in vitro and in an experimental human infection model. Presented at: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy Annual Meeting; 2011 Sep 17-20; Chicago. Presentation V-1557-BTA798. ICAAC. 2013.
  • 84
    Biota Press Release. HRV phase IIb study achieves primary endpoint. Available at www.biotapharma.com/uploaded/154/1021819_20hrvp-haseiibstudyachieve.pdf. (Accessed 16 May 2013)
  • 85
    Hayden FG, Albrecht JK, Kaiser DL, Gwaltney JM Jr. Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon. N Engl J Med 1986; 314:7175.
  • 86
    Douglas RM, Moore BW, Miles HB et al. Prophylactic efficacy of intranasal alpha 2-interferon against rhinovirus infections in the family setting. N Engl J Med 1986; 314:6570.
  • 87
    Synairgen Press Release. Positive phase II asthma clinical trial data. Available at http://www.synairgen.com/media/1536/19%20april%202012%20Phase%20II%20press%20release%20final.pdf. (Accessed 16 May 2013)
  • 88
    Furuta Y, Takahashi K, Shiraki K et al. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 2009; 82:95102.
  • 89
    de Chassey B, Meyniel-Schicklin L, Aublin-Gex A, Andre P, Lotteau V. Genetic screens for the control of influenza virus replication: from meta-analysis to drug discovery. Mol BioSyst 2012; 8:12971303.
  • 90
    Smith SB, Dampier W, Tozeren A, Brown JR, Magid-Slav M. Identification of common biological pathways and drug targets across multiple respiratory viruses based on human host gene expression analysis. PLoS ONE 2012; 7:e33174.